

۱ **Isolation and Antibacterial Properties of *Actinomycetes* from Yellow Olive Tree (*Olea***
۲ ***europaea*)**

۳
۴ **Pardis Nemati**

۵ Department of Microbiology, Faculty of Veterinary Sciences, Ilam University, Ilam, Iran

۶ **Mostafa Nemati**

۷ Department of Microbiology, Faculty of Veterinary Sciences, Ilam University, Ilam, Iran

۸ **Fazel Pourahmad**

۹ Department of Microbiology, Faculty of Veterinary Sciences, Ilam University, Ilam, Iran

۱۰ **Corresponding Author:**

۱۱ Mostafa Nemati

۱۲ Associate Professor

۱۳ Department of Microbiology, Ilam University, Ilam, Iran

۱۴ m.nemati@ilam.ac.ir

۱۵ m26nemati48@gmail.com

۱۶ Mobile phone: 09181413378

22 Abstract

23 The symbiotic relationships between Actinomycetes and their host plants further enhance their
24 potential as sources of bioactive compounds. These bacteria produce a wide array of secondary
25 metabolites with antimicrobial, insecticidal, and anticancer properties, making them valuable for
26 bioprospecting in pharmaceuticals and agriculture.

27 The ineffectiveness of existing antibiotics has resulted in higher morbidity and mortality rates,
28 alongside escalating healthcare costs due to treatment failures. The rise of multidrug-resistant
29 (MDR) pathogens poses a significant threat to global health, necessitating the discovery of novel
30 antimicrobial agents. This study isolates and characterizes endophytic *Actinomycetes* from the
31 yellow olive tree (*Olea europaea*), a plant known for its rich phytochemical composition, to
32 evaluate their antibacterial potential against ESKAPE pathogens. Samples were collected from
33 olive tree roots, and 54 bacterial isolates were obtained, with 45 (83.3%) identified as
34 *Actinomycetes* through 16S rRNA gene amplification. Among these, 16 isolates (35.6%) exhibited
35 antibacterial activity against drug-sensitive and drug-resistant strains of *Staphylococcus aureus*,
36 *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*. Molecular screening revealed that 66.7%,
37 28.9%, and 93.3% of the isolates harbored non-ribosomal peptide synthetase (*NRPS*), polyketide
38 synthase I (*PKS-I*), and polyketide synthase II (*PKS-II*) genes, respectively, which are associated
39 with the biosynthesis of secondary metabolites. However, no direct correlation was found between
40 these biosynthetic genes and antibacterial activity, suggesting that gene expression and
41 environmental factors play crucial roles in metabolite production. The study highlights the
42 potential of endophytic *Actinomycetes* from *Olea europaea* as a source of novel antimicrobial
43 compounds, particularly in the fight against MDR pathogens. These findings underscore the

importance of exploring plant-associated microbes for developing new therapeutic agents to address the global antibiotic resistance crisis.

Keywords: Endophytic *Actinomycetes*, *Olea europaea*, Antibacterial activity, Biosynthetic gene clusters, Secondary metabolites

1. Introduction

The global health landscape is increasingly threatened by the rise of multidrug-resistant (MDR) pathogens, a crisis fueled by the overuse and misuse of antibiotics. This phenomenon has led to the emergence of "superbugs," pathogens resistant to multiple conventional antibiotics, making infections increasingly difficult to treat and pose a significant challenge to public health systems worldwide (1). The World Health Organization (WHO) has identified these MDR pathogens as critical threats, underscoring the urgent need for innovative antimicrobial strategies to combat this escalating crisis (2).

The ineffectiveness of existing antibiotics has resulted in higher morbidity and mortality rates, alongside escalating healthcare costs due to treatment failures (3). In response, researchers are exploring alternative therapies and novel antimicrobial agents, particularly from natural sources, to address the growing threat of antibiotic resistance. Recent advancements in natural product screening, marine-derived compounds, hybrid molecules, and microbial isolates have shown promise in identifying new antimicrobial agents (4). These efforts highlight the importance of leveraging natural biodiversity in the search for effective treatments against resistant pathogens.

Among the most promising sources of novel antimicrobial compounds are the *Actinomycetes*, a phylum of gram-positive bacteria renowned for their prolific production of secondary metabolites,

including antibiotics and bacteriocins. These bacteria, particularly those within the genus *Streptomyces*, are responsible for producing approximately two-thirds of all known natural antibiotics, making them invaluable in the fight against antibiotic resistance (5). *Actinomycetes* are ecologically versatile, thriving in diverse environments such as soil, marine ecosystems, and plant tissues, where they contribute to nutrient cycling, secondary metabolite production, and plant health (6). The production of these bioactive compounds is largely governed by biosynthetic gene clusters (BGCs), which encode the enzymatic machinery required for synthesizing secondary metabolites with diverse biological activities, including antibacterial, antifungal, and anticancer properties. The presence and diversity of BGCs in *Actinomycetes* are strongly correlated with their antimicrobial potential, as these gene clusters enable the production of structurally complex and functionally potent compounds that can target resistant pathogens (7).

The symbiotic relationships between *Actinomycetes* and their host plants further enhance their potential as sources of bioactive compounds. These bacteria produce a wide array of secondary metabolites with antimicrobial, insecticidal, and anticancer properties, making them valuable for bioprospecting in pharmaceuticals and agriculture (8). Endophytic *Actinomycetes*, in particular, have been shown to promote plant growth, protect against pathogens, and produce antibacterial compounds, highlighting their potential applications in sustainable agriculture and medicine (9).

Given the medicinal significance of the yellow olive tree (*Olea europaea*) and its rich phytochemical composition, this study focuses on isolating and characterizing endophytic *Actinomycetes* from *Olea europaea*. The research aims to evaluate the antibacterial properties of these *Actinomycetes* against a panel of pathogenic bacteria, including drug-resistant strains, thereby contributing to the ongoing search for novel antimicrobial agents. By exploring the synergistic potential of *Olea europaea* and its associated *Actinomycetes*, this study seeks to

advance our understanding of natural sources of antibiotics and their applications in combating MDR pathogens.

2. Materials and Methods

2.1 Sample Collection and Isolation of *Actinomycetes*

In this study, which was conducted in 2023, ten yellow olives (*Olea europaea*) saplings were obtained from the greenhouse of Ilam University, Iran, and transferred to the Microbiology laboratory.

In the laboratory, plant samples underwent a modified six-step surface sterilization procedure within 24 hours, as described in previous research (10). This involved washing with tap water for 10 minutes to remove soil and contaminants, followed by sterile separation of root, stem, and leaf tissues. The tissues were sequentially sterilized using 70% ethanol (1 minute), 5% sodium hypochlorite (3 minutes), 70% ethanol (30 seconds), and 3% sodium thiosulfate, then rinsed three times with sterile distilled water. The sterilized tissues were cut into 5 mm pieces and placed on starch casein agar (SCA) supplemented with cycloheximide (50 µg/mL) and nalidixic acid (20 µg/mL) to inhibit fungal and non-actinomycete bacterial growth (11).

Cultures were incubated at 28 °C for up to four weeks, with regular monitoring for colony growth. Putative actinomycete colonies were purified by repeated streaking on ISP2 medium. To verify the effectiveness of the sterilization process, 100 µL of the final rinse solution was plated on SCA and incubated at 28 °C for two weeks.

2.2 DNA Isolation and Molecular Identification of *Actinomycetes*

109 Genomic DNA extractions were conducted for all endophytic isolates using a straightforward
 110 boiling method, as outlined in earlier studies (12) followed by polymerase chain reaction (PCR)
 111 with taxon-specific primers (Table 1) to identify actinomycetes, as previously demonstrated (13).

112 **Table 1.** List of oligonucleotide primers used in the study

Primer name	Sequence (5'-3')	Gene	Product size (bp)	Reference
ACT235f	CGCGGCCTATCAGCTTGTTG	16S rRNA	640	(13)
ACT878r	CCGTACTCCCCAGGCGGGG			
A3F	GCSTACSYSATSTACACSTCSGG	NRPS	700-800	(14)
A7R	SASGTCVCCSGTSCGGTAS			
KIF	TSAAGTCSAACATCGGBCA	PKS-I	1200-1400	(15)
M6R	CGCAGGTTSCSGTACCAGTA			
PKS-II-A	TSGCSTGCTTCGAYGCSATC	PKS-II	600	(14)
PKS-II-B	TGGAANCCGCCGAABCCGCT			

113

114 2. 3 Evaluation of Antibacterial Activity of *Actinomycetes*

115 All actinomycetal isolates were fermented, and their resulting extracts were screened according to
 116 previous research without modifications (11).

117 The drug-sensitive and drug-resistant bacteria, as selective members of the ESKAPE pathogens
 118 (16), were used to assess the antibacterial activity of the actinomycetal strains (Table 2). These
 119 bacteria were grown overnight at 37°C in Mueller-Hinton (MH) broth, which was subsequently
 120 adjusted to a 0.5 McFarland standard turbidity (approximately 1.5×10^8 CFU/mL).

121 Bacterial lawns were prepared on Mueller-Hinton (MH) agar with 6 mm wells, following the
 122 procedure outlined by Hajizadeh et al. (10). Into each well, 100 μ L of crude extracts were added.

123 The plates were left at room temperature for one hour before incubating at 37°C for 24 hours. After

124 incubation, the inhibition zones were measured millimeters (mm) using 100 μ L of ethyl acetate as
125 a control.

126 **Table 2. Members of ESKAPE pathogens included in the study for evaluating antibacterial activity**

Bacteria	Drug-sensitive	Drug-resistant
<i>Staphylococcus aureus</i>	ATCC 25923	ATCC 33591
<i>Klebsiella pneumoniae</i>	ATCC 10031	ATCC 700603
<i>Pseudomonas aeruginosa</i>	ATCC 27853	ATCC 2774
<i>Acinetobacter baumannii</i>	ATCC BAA-747	

127

128 **2.4 Detection of *PKS-I*, *PKS-II*, and *NRPS* genes**

129 Genes encoding non-ribosomal peptide synthetases (*NRPS*) and polyketide synthases I and II
130 (*PKS-I* and *PKS-II*) were detected via PCR using specific primers (Table 1). Amplifications were
131 performed with 30 cycles of denaturation (95°C, 1 minute), annealing (58°C or 60°C, 1 minute),
132 and extension (72°C, 1 minute). Products were analyzed on 1.5% agarose gels.

133 **3. Results**


134 **3.1. Phenotypic Identification of *Actinomycetes***

135 Endophytic isolates exhibiting chalky, hard, and leathery colony morphologies on culture media,
136 particularly those with distinct color variations between the upper and lower surfaces, were
137 preliminarily identified as *Actinomycetes*. Based on these characteristics, 54 isolates, all recovered
138 from olive tree roots, were classified as *Actinomycetes*.

139 **3.2. Molecular Identification of *Actinomycetes***

140 PCR amplification of the 16S rRNA gene was performed on DNA extracted from the isolated
141 endophytes. A positive PCR product was obtained for 45 out of 54 strains (83.3%). Consequently,

142 subsequent molecular analyses and phenotypic evaluations of antimicrobial properties were
143 conducted on these 45 actinomycete isolates. Figure 1 illustrates the positive PCR amplification
144 of the 16S rRNA gene for several endophytic isolates in this study.



145

146

147 **Figure 1: Results of PCR product electrophoresis for several endophytic isolates in this**
148 **study.**

- 149 • Lanes: M) DNA size marker, 1) Negative control, 2-19) PCR products of the isolates
150 (640 base pairs)


151 **3.3. Antimicrobial Activity of Isolated *Actinomycetes***

152 The antimicrobial activity of *Actinomycetes* isolated from olive trees was assessed by measuring
153 the diameter of the clear zone surrounding the wells. Among the 45 isolates with a positive PCR
154 result for the 16S rRNA gene, 16 isolates (35.6%) exhibited antimicrobial activity against the
155 tested pathogenic bacteria. Of these 16 isolates, 12 (75%) were active against drug-sensitive
156 *Staphylococcus aureus*, 11 (68.8%) against drug-sensitive *Pseudomonas aeruginosa*, 4 (25%)
157 against drug-resistant *S. aureus*, 7 (43.8%) against drug-resistant *Klebsiella pneumoniae*, 2
158 (12.5%) against drug-resistant *P. aeruginosa*, and 5 (31.25%) against drug-sensitive *K.*


109 *pneumoniae*. None of the *Actinomycetes* in this study exhibited activity against *Acinetobacter*
160 *baumannii*.

161 **3.4. PCR Screening for *NRPS*, *PKS-I*, and *PKS-II* Genes**

162 In addition to phenotypic evaluation of antimicrobial activity, the presence of *NRPS*, *PKS-I*, and
163 *PKS-II* genes was investigated in the *Actinomycetes* with positive 16S rRNA gene PCR results. Of
164 the 45 isolates, 30 (66.7%) possessed the *NRPS* gene with a length of 700-800 base pairs, 13
165 (28.9%) harbored the *PKS-I* gene with a length of 1200 base pairs, and 42 (93.3%) carried the
166 *PKS-II* gene with a length of 600 base pairs (Figures 2-4).



167
168 **Figure 2. Agarose gel electrophoresis of *NRPS* gene PCR products from actinomycetal**
169 **isolates.**
170 Lanes: M) DNA size marker; 1) Positive control; 2) Negative control; 3–18) PCR products from
171 actinomycete isolates, displaying bands between 700–800 bp, indicative of the amplified *NRPS*
172 gene.



174

175 **Figure 3. Agarose gel electrophoresis of *PKS-I* gene PCR products from actinomycetal**
 176 **isolates.**

177 Lanes: M) DNA size marker; 1: Negative control; 2–19) PCR products from actinomycete
 178 isolates showing a band at approximately 1200-1400 bp, representing the amplified *PKS-I* gene.

179

180



181

182 **Figure 4. Agarose gel electrophoresis of *PKS-II* gene PCR products from actinomycetal**
 183 **isolates.**

184 Lanes M) DNA size marker; 1) Negative control; 2–19) PCR products from actinomycete
 185 isolates exhibiting a band at 600 bp, corresponding to the amplified *PKS-II* gene.

186

187

188 **3.5. Correlation between Antimicrobial Activity and presence of Biosynthetic Gene Clusters**

189 The relationship between antimicrobial activity and BGCs is detailed in Table 3. Strains with
190 identified BGCs often exhibit antibacterial activity, highlighting the role of these clusters in
191 producing antimicrobial compounds. Strains possessing *PKS-II* and *NRPS* clusters are more likely
192 to show activity against both drug-resistant and drug-sensitive pathogens.

193 Notably, strains Z10 and Z36, which contain all three types of clusters, demonstrated strong
194 antibacterial effects against multiple pathogens. While antimicrobial activity was observed against
195 drug-sensitive pathogens as well, the presence of BGCs in these cases was less consistent.

196

197

Table 3. Correlation between the Antibacterial Activity and the presence of BGCs

No	Code	NRPS	PKS- I	PKS- II	33591 ^a	2774 ^b	700603 ^c	10031 ^d	27853 ^e	25923 ^f	BAA- 747
1	Z2	*		*							
2	Z4		*	*							
3	Z5	*		*			*		*	*	
4	Z6	*		*							
5	Z7	*		*							
6	Z8	*	*	*							
7	Z9	*		*						*	
8	Z10	*	*	*				*	*	*	
9	Z11				*		*	*	*	*	
10	Z12		*	*							
11	Z13	*		*						*	
12	Z15	*		*					*	*	
13	Z16								*		
14	Z17	*		*					*	*	
15	Z18	*							*	*	
16	Z19			*							
17	Z22	*		*							
18	Z23	*		*							
19	Z24	*		*							
20	Z25	*		*							
21	Z26	*		*							
22	Z27	*	*	*	*				*	*	
23	Z28	*		*							
24	Z29		*	*							
25	Z31			*		*					
26	Z32	*	*	*							
27	Z33	*		*							
28	Z34			*							
29	Z35		*	*							
30	Z36		*	*	*	*	*	*	*	*	
31	Z37	*		*							
32	Z38	*	*	*			*	*	*	*	
33	Z39		*	*							
34	Z41	*	*	*							
35	Z42			*							
36	Z43	*		*							
37	Z44	*		*							
38	Z45	*		*							
39	Z46	*		*							
40	Z48		*	*	*		*	*	*	*	
41	Z49			*			*				
42	Z50			*			*				
43	Z51	*		*							
44	Z52	*		*							
45	Z54	*		*							

199 a= *S. aureus* (ATCC 33591) (Drug resistant); b= *P. aeruginosa* (ATCC 2774) (Drug resistant); c= *K. pneumoniae* (ATCC
200 700603) (Drug resistant); d= *K. pneumoniae* (ATCC 10031) (Drug sensitive); e= *P. aeruginosa* (ATCC 27853) (Drug sensitive);
201 f= *S. aureus* (ATCC 25923) (Drug sensitive); g= *A. baumannii* (ATCC BAA-747).

2.2 4. Discussion

2.3 The study of 54 bacterial isolates revealed that 45 (83.33%) were identified as *Actinomycetes*, all
2.4 sourced from the root tissues of the plant. This finding aligns with existing literature that highlights
2.5 the dominant role of *Actinomycetes* in plant root microbiomes, where they contribute to plant
2.6 health and secondary metabolite production (17). Roots serve as primary sites for endophytic
2.7 colonization due to their direct contact with soil, which acts as a reservoir for *Actinomycetes*. The
2.8 function of roots as "gatekeepers" has been described, showing how they selectively screen soil
2.9 bacteria, resulting in a microbiome that is predominantly composed of *Actinomycetota*, including
2.10 *Actinomycetes* (8). This selective colonization is essential for plant growth and stress resistance.

2.11 The presence of biosynthetic genes, such as nonribosomal peptide synthetases (*NRPS*) and
2.12 polyketide synthases (*PKS-I* and *PKS-II*), in a significant percentage of isolates, highlights the
2.13 potential of *Actinomycetes* to produce diverse secondary metabolites. Specifically, frequencies of
2.14 these genes were reported as 66.7% for *NRPS*, 28.9% for *PKS-I*, and 93.3% for *PKS-II* among
2.15 isolates from *Olea europaea*. This suggests that *Actinomycetes* associated with this plant could be
2.16 valuable sources for discovering novel bioactive compounds, particularly antimicrobial agents, as
2.17 these gene clusters are often linked to the biosynthesis of such metabolites (17). However, the
2.18 absence of a direct correlation between biosynthetic genes and antibacterial activity indicates that
2.19 additional factors, such as gene expression, regulatory mechanisms, and environmental conditions,
2.20 play crucial roles in the production of bioactive compounds. For instance, it has been noted that
2.21 while many actinomycetes harbor biosynthetic gene clusters, not all express these genes under
2.22 laboratory conditions, leading to variability in antimicrobial activity (18). The antibacterial activity
2.23 of the isolates against drug-resistant pathogens is particularly significant given the global rise in
2.24 antibiotic resistance, which poses a major public health challenge. Among the 45 isolates studied,

۲۲۵ 16 (35.6%) demonstrated antibacterial activity, with the highest efficacy observed against drug-
۲۲۶ sensitive *S. aureus* and *P. aeruginosa*. This finding is crucial as these bacteria are common causes
۲۲۷ of infections and are often resistant to multiple antibiotics (19). The identification of isolates with
۲۲۸ significant antibacterial properties against these pathogens suggests potential avenues for
۲۲۹ developing new therapeutic agents (20). Moreover, research into endophytic *Actinomycetes* from
۲۳۰ medicinal plants supports their antibacterial potential. It has been reported that 69% of isolates
۲۳۱ from medicinal plants in Iran exhibited antimicrobial activity against various pathogens, including
۲۳۲ *S. aureus* and *Escherichia coli* (21).

۲۳۳ In this study, strains Z10 and Z36 were identified as particularly noteworthy due to their possession
۲۳۴ of all three types of BGCs and their pronounced antibacterial activity. These findings align with
۲۳۵ previous research demonstrating the antimicrobial potential of *Actinomycetes* isolates harboring
۲۳۶ multiple BGCs. For instance, *Streptomyces* sp. KN37, isolated from extreme environments,
۲۳۷ exhibited robust antimicrobial activity and contained 41 predicted BGCs, some of which resemble
۲۳۸ known antibiotic-producing gene clusters, underscoring its potential for novel antibacterial
۲۳۹ compound discovery (22). Similarly, *Actinomycetes* isolates from mangrove sediments revealed
۲۴۰ that 19 strains possessed BGCs, with three displaying significant antibacterial activity against
۲۴۱ pathogens such as *S. aureus* and *E. coli*, further supporting the correlation between BGC presence
۲۴۲ and antimicrobial efficacy (23).

۲۴۳ Despite the presence of biosynthetic genes in some isolates, the absence of antibacterial activity
۲۴۴ suggests that these genes may be silent or require specific activation conditions. It was found that
۲۴۵ many *Actinomycetes* from mangrove sediments contained biosynthetic gene clusters but exhibited
۲۴۶ limited antibacterial activity, indicating that the presence of these genes does not guarantee
۲۴۷ expression under standard conditions (24).

248 The phenomenon of "cryptic biosynthesis" is prevalent in *Actinomycetes*, where many biosynthetic
249 gene clusters remain silent under standard laboratory conditions. Advanced techniques such as
250 genome mining and metabolic engineering are essential to unlock their full biosynthetic potential.
251 Strategies such as co-cultivation, external cues, and genetic manipulation have been employed to
252 activate these silent pathways, revealing previously uncharacterized compounds (24).
253 Additionally, the identification of isolates exhibiting antibacterial activity without known
254 biosynthetic genes suggests alternative mechanisms for antibiotic production. Research indicates
255 that atypical response regulators and alternative sigma factors can modulate antibiotic biosynthesis
256 through mechanisms not yet fully understood (25). This underscores the need for further
257 investigation into these alternative pathways to enhance our understanding of antibiotic production
258 and discover new therapeutic agents.

259 The isolation of *Actinomycetes* from *Olea europaea* is significant for drug discovery, particularly
260 in addressing multidrug-resistant infections. Research shows that extracts from *Olea europaea*
261 exhibit antibacterial activity against various resistant strains, including *Mycobacterium*
262 *tuberculosis* (26). The presence of bioactive compounds such as oleuropein in olive leaves
263 contributes to their antimicrobial properties, making them potential candidates for developing new
264 antibiotics (27). Furthermore, the traditional use of *Olea europaea* in various cultures for treating
265 infections highlights its therapeutic potential. The exploration of its *Actinomycetes* isolates could
266 lead to the discovery of novel antimicrobial agents capable of combating the growing challenge of
267 antibiotic resistance (28). Overall, this study enriches our understanding of plant-based
268 antimicrobial properties and opens avenues for innovative drug development against resistant
269 pathogens.

270

۲۷۱ **Conflict of Interest**

۲۷۲ The authors declare that they have no conflict of interest.

۲۷۳ **Acknowledgment**

۲۷۴ The authors express gratitude to the Vice Chancellor for Research and Technology at Ilam
۲۷۵ University, Ilam, Iran, for their partial financial support of this study.

۲۷۶ **Ethics**

۲۷۷ This paper does not involve research related to experimental animals or specific human diseases.

۲۷۸ **Data Availability**

۲۷۹ The data supporting the findings of this study are not publicly available due to not being necessary
۲۸۰ for the public. However, they can be made available upon request from the corresponding author.

۲۸۱ **Authors' Contributions**

۲۸۲ 1- Study concept and design: P. N., and M. N.

۲۸۳ 2- Acquisition of data: P. N., and F. P.

۲۸۴ 3- Analysis and interpretation of data: P. N., F. P., and M. N.

۲۸۵ 4- Drafting of the manuscript: P. N. and F. P.

۲۸۶ 5- Critical revision of the manuscript for important intellectual content: F. P., and M. N.

۲۸۷ 6- Statistical analysis: P. N., and M. N.

۲۸۸ 7- Administrative, technical, and material support: F. P., and M. N.

۲۸۹ 8- Study supervision: F. P., and M. N.

۲۹۰

291 **References**

- 292 1. Hernando-Amado S, Coque TM, Baquero F, Martínez JL. Defining and combating
293 antibiotic resistance from One Health and Global Health perspectives. *Nature Microbiology*.
294 2019;4(9):1432-42. <https://doi.org/10.1038/s41564-019-0503-9>
- 295 2. Rajput P, Nahar KS, Rahman KM. Evaluation of antibiotic resistance mechanisms in
296 gram-positive bacteria. *Antibiotics*.
297 2024;13(12):1197. <https://doi.org/10.3390/antibiotics13121197>
- 298 3. Puyol McKenna P, Naughton PJ, Dooley JS, Ternan NG, Lemoine P, Banat IM.
299 Microbial biosurfactants: Antimicrobial activity and potential biomedical and therapeutic
300 exploits. *Pharmaceuticals*. 2024;17(1):138. <https://doi.org/10.3390/ph17010138>
- 301 4. Shang Z, Sharma V, Pai L, Kumar T, Patil S. Optimizing the production and efficacy of
302 antimicrobial bioactive compounds from *Streptomyces kanamyceticus* in combating multi-drug-
303 resistant pathogens. *Frontiers in Cellular and Infection Microbiology*.
304 2025;14:1500440. <https://doi.org/10.3389/fcimb.2024.1500440>
- 305 5. Nouioui I, Zimmermann A, Hennrich O, Xia S, Rössler O, Makitrynsky R, et al.
306 Challenging old microbiological treasures for natural compound biosynthesis capacity. *Frontiers*
307 *in Bioengineering and Biotechnology*.
308 2024;12:1255151. <https://doi.org/10.3389/fbioe.2024.1255151>
- 309 6. Girão M, Alexandrino DA, Cao W, Costa I, Jia Z, Carvalho MF. Unveiling the culturable
310 and non-culturable actinobacterial diversity in two macroalgae species from the northern
311 Portuguese coast. *Environmental Microbiology*.
312 2024;26(4):e16620 . <https://doi.org/10.1111/1462-2920.16620>

- 313 7. Xue Y, Zhou Z, Feng F, Zhao H, Tan S, Li J, et al. Genomic Analysis of *Kitasatospora*
314 *setae* to Explore Its Biosynthetic Potential Regarding Secondary Metabolites. *Antibiotics*.
315 2024;13(5):459. <https://doi.org/10.3390/antibiotics13050459>
- 316 8. Thakur N, Nigam M, Mann NA, Gupta S, Hussain CM, Shukla SK, et al. Host-mediated
317 gene engineering and microbiome-based technology optimization for sustainable agriculture and
318 environment. *Functional & Integrative Genomics*.
319 2023;23(1):57. <https://doi.org/10.1007/s10142-023-00982-9>
- 320 9. Mahmoud AM, Reyad AM, Khalaf MH, Sheteiwy MS, Dawood MF, El-Sawah AM, et
321 al. Investigating the endophyte *Actinomycetota* sp. JW0824 strain as a potential bioinoculant to
322 enhance the yield, nutritive value, and chemical composition of different cultivars of anise
323 (*Pimpinella anisum*) seeds. *Biology*. 2024;13(8):553. <https://doi.org/10.3390/biology13080553>
- 324 10. Qin S, Xing K, Jiang J-H, Xu L-H, Li W-J. Biodiversity, bioactive natural products, and
325 biotechnological potential of plant-associated endophytic actinobacteria. *Applied Microbiology*
326 *and Biotechnology*. 2011;89(3):457-73. <https://doi.org/10.1007/s00253-010-2923-6>
- 327 11. Hajizadeh M, Pourahmad F, Nemati M. Isolation and screening of antibacterial activity
328 of *Actinomycetota* from the medicinal plant, *Anthemis pseudocotula* Boiss. *Archives of Razi*
329 *Institute*. 2023;78(5):1638-1646. <https://doi.org/10.22092/ari.2023.78.5.1638>
- 330 12. Tavarideh F, Pourahmad F, Nemati M. Diversity and antibacterial activity of endophytic
331 bacteria associated with medicinal plant *Scrophularia striata*. *Veterinary Research Forum*.
332 2022;13(3):409-15. <https://doi.org/10.30466/vrf.2021.529714.3174>

- 333 13. Stach J, Maldonado LA, Ward AC, Goodfellow M, Bull AT. New primers for the
334 class *Actinobacteria*: application to marine and terrestrial environments. Environmental
335 Microbiology. 2003;5(10):828-841. <https://doi.org/10.1046/j.1462-2920.2003.00483.x>
- 336 14. Ayuso-Sacido A, Genilloud O. New PCR primers for the screening of NRPS and PKS-I
337 systems in *Actinomycetes*: Detection and distribution of these biosynthetic gene sequences in
338 major taxonomic groups. Microbial Ecology. 2004;49(1):10-24. [https://doi.org/10.1007/s00248-
339 004-0249-6](https://doi.org/10.1007/s00248-004-0249-6)
- 340 15. Metsä-Ketelä M, Salo V, Halo L, Hautala A, Hakala J, Mäntsälä P, et al. An efficient
341 approach for screening minimal PKS genes from *Streptomyces*. FEMS Microbiology Letters.
342 1999;180(1):1-6. <https://doi.org/10.1111/j.1574-6968.1999.tb08770.x>
- 343 16. Miller WR, Arias CA. ESKAPE pathogens: antimicrobial resistance, epidemiology,
344 clinical impact, and therapeutics. Nature Reviews Microbiology. 2024;1-
345 19. <https://doi.org/10.1038/s41579-024-01054-w>
- 346 17. Anavadiya B, Chouhan S, Saraf M, Goswami D. Exploring endophytic actinomycetes: A
347 rich reservoir of diverse antimicrobial compounds for combatting global antimicrobial resistance.
348 The Microbe. 2024;100110. <https://doi.org/10.1016/j.microb.2024.100110>
- 349 18. Scherlach K, Hertweck C. Mining and unearthing hidden biosynthetic potential. Nature
350 Communications. 2021;12:3864. <https://doi.org/10.1038/s41467-021-24133-5>
- 351 19. Ahmed K, Ahmed H, Ahmed FA, Ali AA, Akbar J, Rana J, et al. Analysis of anti-
352 microbial and anti-biofilm activity of hand washes and sanitizers against *S. aureus* and *P.*
353 *aeruginosa*. Journal of the Pakistan Medical Association.
354 2020;2019. <https://doi.org/10.5455/jpma.2776>

- 300 20. Thangamani S, Younis W, Seleem MN. Repurposing clinical molecule ebselen to combat
306 drug-resistant pathogens. PLoS One.
307 2015;10(7):e0133877 . <https://doi.org/10.1371/journal.pone.0133877>
- 308 21. Beiranvand M, Amin M, Hashemi-Shahraki A, Romani B, Yaghoubi S, Sadeghi P.
309 Antimicrobial activity of endophytic bacterial populations isolated from medical plants of Iran.
310 Iranian Journal of Microbiology. 2017;9(1):11. <https://pubmed.ncbi.nlm.nih.gov/28775818/>
- 311 22. Zhao J, Li Q, Zeeshan M, Zhang G, Wang C, Han X, et al. Integrative Genomics and
312 Bioactivity-guided isolation of Novel Antimicrobial compounds from *Streptomyces* sp. KN37 in
313 Agricultural Applications. Molecules. 2024;29(9):2040. <https://www.mdpi.com/1420-3049/29/9/2040>
- 314 [3049/29/9/2040](https://www.mdpi.com/1420-3049/29/9/2040)
- 315 23. Anggelina AC, Pringgenies D, Setyati WA. Presence of biosynthetic gene clusters
316 (NRPS/PKS) in actinomycetes of mangrove sediment in Semarang and Karimunjava, Indonesia.
317 Environment and Natural Resources Journal.
318 2021;19(5). <https://doi.org/10.32526/ENNRJ/19/202100050>
- 319 24. Vikeli E, Widdick DA, Batey SF, Heine D, Holmes NA, Bibb MJ, et al. In situ activation
320 and heterologous production of a cryptic lantibiotic from an African plant ant-
321 derived *Saccharopolyspora* species. Applied and Environmental Microbiology.
322 2020;86(3):e01876-19 . <https://doi.org/10.1128/AEM.01876-19>
- 323 25. Tu B, Mao Y, Wang R, Kang Y, Ye J, Zhang H, Wu H. An alternative σ factor σ_{Lsl}
324 regulates lincomycin production in *Streptomyces lincolnensis*. Journal of Basic Microbiology.
325 2023;63(2):190-9. <https://doi.org/10.1002/jobm.202200485>

- 376 26. Camacho-Corona MD, Ramírez-Cabrera MA, Santiago OG, Garza-González E, Palacios
377 ID, Luna-Herrera J. Activity against drug-resistant tuberculosis strains of plants used in Mexican
378 traditional medicine to treat tuberculosis and other respiratory diseases. *Phytotherapy Research*.
379 2008;22(1):82-5. <https://doi.org/10.1002/ptr.2269>
- 380 27. Nediani C, Ruzzolini J, Romani A, Calorini L. Oleuropein, a bioactive compound
381 from *Olea europaea* L., as a potential preventive and therapeutic agent in non-communicable
382 diseases. *Antioxidants*. 2019;8(12):578. <https://doi.org/10.3390/antiox8120578>
- 383 28. Ayoub L, Hassan F, Hamid S, Abdelhamid Z, Souad A. Phytochemical screening,
384 antioxidant activity and inhibitory potential of *Ficus carica* and *Olea europaea* leaves.
385 *Bioinformation*. 2019;15(3):226. <https://doi.org/10.6026/97320630015226>

386